Immunosuppression preventing concordant xenogeneic islet graft rejection is not sufficient to prevent recurrence of autoimmune diabetes in nonobese diabetic mice

Transplantation

Volumn 65, Issue 10, 1998, Pages 1310-1314

  Guo, Zhiguang ^a   Mital, Deepak ^a   Shen, Jikun ^a   Chong, Anita S F ^a   Tian, Ye ^a   Foster, Preston ^a   Sankary, Howard ^a   McChesney, Lawrence ^a   Jensik, Stephen C ^a   Williams, James W ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; AUTOIMMUNE DISEASES; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; GRAFT REJECTION; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; ISOXAZOLES; MICE; MICE, INBRED NOD; MICE, INBRED STRAINS; RATS; RATS, SPRAGUE-DAWLEY; RECURRENCE; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032572015     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199805270-00005     Document Type: Article

References (45)

1. Lacy PE, Davie JM, Finke EH. Prolongation of islet allograft survival following in vitro culture (24°C) and a single injection of ALS. Science 1979; 204: 312.
2. Lau H, Reemtsma K, Hardy MA. Prolongation of rat islet allograft survival by direct ultraviolet irradiation of the graft. Science 1984; 223: 607.
3. Shizuru JA, Gregory AK, Chao CTB, Fathman CD. Islet survival after a single course of treatment of recipient with antibody to L3T4. Science 1987; 237: 278.
4. Terada M, Salzler M, Lennartz K, Mullen Y. The effect of H-2 compatibility on pancreatic beta cell survival in the nonobese diabetic mouse. Transplantation 1988; 45: 622.
5. Wang Y, Pontesilli O, Gill RG, La Rosa FG, Lafferty KJ. The role of CD4+ and CD8+ T cells in the destruction of islet graft by spontaneously diabetic mice. Proc Natl Acad Sci USA 1991; 88: 527.
6. Wang Y, McDuffie M, Nomikos IN, Hao L, Lafferty K. Effect of cyclosporine on immunologically mediated diabetes in nonobese diabetic mice. Transplantation 1988; 46: 101S.
7. Prowse SJ, Bellgrau D, Lafferty K. Islet allografts are destroyed by disease occurrence in the spontaneously diabetic BB rats. Diabetes 1986; 35: 110.
8. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996; 85: 291.
9. Katz JD, Wangt B, Haskins K, Benoist C, Mathis D. Following a diabetogenic T cell from genesis through pathogenesis. Cell 1993; 74: 1089.
10. Serreze DV, Leiter EH, Christianson GJ, Greiner D, Roopenian DC. Major histocompatibility complex I deficient NOD-B2 m null mice are diabetes and insulitis resistant. Diabetes 1994; 43: 505.
11. Wicker LS, Leiter EH, Todd JA, et al. B2-microglobulin deficient NOD mice do not develop insulitis or diabetes. Diabetes 1994; 43: 500.
12. Thivolet C, Bendelac A, Bedossa P Bach JF, Carnaud C. CD8+ T cell homing to the pancreas in the nonobese diabetic mouse is CD4+ T cell-dependent. J Immunol 1991; 146: 85.
13. Yagi H, Matsumoto M, Kunimoto K, et al. Analysis of the roles of CD4+ and CD8+ T cells in autoimmune diabetes of NOD mice using transfer to NOD athymic nude mice. Eur J Immunol 1992; 22: 2387.
14. Bartlett ST, Chin T, Dirden B, Quereshi A, Hadley G. Inclusion of peripancreatic lymph node cells prevent recurrence autoimmune destruction of islet transplant: evidence of donor chimerism. Surgery 1995; 118: 392.
15. Stegall MD, Lafferty KJ, Kam I, Gill RG. Evidence of recurrent autoimmunity in human allograft islet transplantation. Transplantation 1996; 61: 1272.
16. Tyden G, Reinholt FP, Sundkvist G, Bolonder J. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 1996; 355: 860.
17. Guo Z, Chong AS, Shen JK, et al. Prolongation of rat allograft survival by the immunosuppressive agent, leflunomide. Transplantation 1997; 63: 711.
18. Wright JR J, Krarns H, MacDonald AS. Leflunomide and cyclosporine A prolong fish-to-mouse islet xenograft survival in Balb/c mice. Transplant Proc 1994; 26: 1310.
19. Lakey JR, Yatscoff RW, Koshal A, Rajotte RV. Prolongation of concordant islet xenograft with leflunomide. Transplant Proc 1996; 28: 816.
20. Williams JW, Xiao F, Foster P, et al. Leflunomide in experimental transplantation: control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation 1994; 57: 1223.
21. D'Silva M, Candinas D, Achilleos O, et al. The immunomodulatory effect of leflunomide in rat cardiac allotransplantation. Transplantation. 1995; 60: 430.
22. McChesney LP, Xiao F, Sankary HN, et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation. 1994; 57: 1717.
23. Xiao F, Chong A, Foster P, et al. Leflunomide on acute rejection in hamster to rat cardiac xenografts. Transplantation 1995; 58: 828.
24. Chong AS, Finnegan A, Jiang X, et al. Leflunomide, a novel immunosuppressive agent: the mechanism of inhibition of T cell proliferation. Transplantation 1993; 55: 1361.
25. Siemasko KF, Chong ASF, Williams JW, Bremer EG, Finnegan A. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996; 61: 635.
26. Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS. Inhibition of protein tyrosine phoshorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995; 270: 12398.
27. Mattar T, Kochhar K, Bartlett R, Bremer EG, Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett 1993; 334: 161.
28. Greene S, Watanabe K, Braatz-Trulson J, Lou L. Inhibition of dihydroorate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995; 50: 861.
29. Williamson RA, Yea CM, Robson PA, et al. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 1995; 270: 22467.
30. Guo Z, Chong AS, Shen JK, et al. In vivo effects of leflunomide on normal pancreatic islet and isogeneic graft function. Transplantation 1997; 63: 716.
31. Inverardi L, Ricordi C. Transplantation of pancreas and islet of Langerhans: a review of progress. Immunol Today 1995; 17: 7.
32. Suarez-Pinzon W, Rajotte RV, Mosmann TR, Rabinovitch A. Both CD4+ and CD8+ T-cells in syngeneic islet grafts in NOD mice produce interferon-r during β-cell destruction. Diabetes 1996; 45: 1350.
33. Chervonsky AV, Wang Y, Wong FS, et al. The role of Fas in autoimmune diabetes. Cell 1997; 89: 17.
34. Yamada K, Takane-Gyotoku N, Yuan X, et al. Mouse islet cell lysis mediated by interleukin-1 induced Fas. Diabetologia 1996; 39: 379.
35. Stassi G, Todaro M, Trucco G, et al. Human insulin-producing beta-cells dye through Fas-mediated apoptosis. Autoimmunity 1996; 24, Suppl.1: 6.
36. Benoist C, Mathis D. Cell death mediators in autoimmune diabetes: no shortage of suspects. Cell 1997; 89: 1.
37. Kurrer MO, Palala SV, Hanson HL, Kata JD. β Cell apoptosis in T cell-mediated autoimmune diabetes. Proc Natl Acad Sci USA 1997; 94: 213.
38. Lang R, Wagner H, Heeg K. Differential effects of the immunosuppressive agents cyclosporine and leflunomide in vivo: leflunomide blocks clonal T cell expansion yet allows production of lymphokines and manifestation of T cell-mediated shock. Transplantation 1995; 59: 382.
39. Gill RG, Coulombe M. Islet xenografting in autoimmune diabetes. Transplant Proc 1994; 26: 1140
40. Mandel TE, Koulmanda M. Xenotransplantation of islets of Langerhans in diabetes mellitus. Transplant Proc 1994; 26: 1110.
41. Henretta J, Pittman K, McFadden T, Thomas F. Successful discordant pancreatic islet xenotransplantation by prevention of primary nonfunction graft rejection and autoimmune disease recurrence. Transplant Proc 1994; 26: 1133.
42. Koike T, Itoh Y, Ishii T, et al. Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes 1987; 36: 539.
43. Shizuru JA, Taylor-Edwards C, Banks BA, Gregory AK, Fathman CG. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science 1988; 240: 659.
44. Baeder WL, Sredy J, Sehgal SN, Chang JY, Adams LM. Rapamycin prevents the onset of insulin-dependent diabetes mellitus in NOD mice. Clin Exp Immunol 1992; 89: 174.
45. Kai N, Motojima K, Tsunoda T, Kanematsu T. Prevention of insultis and diabetes in nonobese diabetes mice by administration of FK506. Transplantation 1993; 55: 936.